Therapeutic Asset Ratings
261 results matching 1 filter
128,359 assets · 8,667 sponsors · 3,127 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
DEXAMETHASONE
precursor lymphoblastic lymphoma/leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(63)
Fludarabine
T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(63)
Fludarabine
B Acute Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2/3
B
(63)
Pcc
hemophilia
Institute of Hematology & Blood Diseases Hospital, China
P4
B
(62)
cc-5013
mantle cell lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(62)
Siltuximab
plasma cell myeloma
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(62)
Fludarabine
BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(62)
Siltuximab
cytokine release syndrome
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(61)
Cyclophosphamide
RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(60)
Cytosin-Arabinosid
RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(60)
Daunorubicin
RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(60)
Idarubicine
RUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(60)
Tafasitamab
follicular lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(60)
Cyclophosphamide
precursor lymphoblastic lymphoma/leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
DARATUMUMAB
adult acute lymphoblastic leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
Fludarabine
T-lymphoblastic lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
Obinutuzumab
aggressive B-cell non-Hodgkin lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
Venetoclax
FLT3 Gene Mutation
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
Venetoclax
mixed phenotype acute leukemia
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
Vinorelbine
Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(60)
Bbm-H901
hemophilia B
Institute of Hematology & Blood Diseases Hospital, China
P2/3
B
(60)
CIS-DIAMMINEDICHLOROPLATINUM II
relapsed/refractory diffuse large B-cell lymphoma
Institute of Hematology & Blood Diseases Hospital, China
P2/3
B
(60)
Blinatumomab
mixed phenotype acute leukemia
Institute of Hematology & Blood Diseases Hospital, China
P3
B
(59)
Flumatinib
acute leukemia
Institute of Hematology & Blood Diseases Hospital, China
P4
B
(58)
cc-5013
Acute Lymphoblastic Leukemia, Adult
Institute of Hematology & Blood Diseases Hospital, China
P2
B
(58)
Showing 51 to 75 of 261 assets
Previous
Page 3 of 11
Next